0,1,2,3,4,5,6
,Table 2 Predicted peptide candidates utilized for screening CD8+ T cells1,,,,,
HLA-A*1101,ANTIGEN,PEPTIDE SEQUENCES,LENGTH,LOCATION,PREDICTED IC50 nM,POOL
HLA-A*1101,GRA15,STSPFATRK,9,152-160,5,P1
HLA-A*1101,GRA15,ASTSPFATRK,10,150-159,18.2,
HLA-A*1101,GRA10,AAAATPGLPK,10,568-577,9,
HLA-A*1101,GRA10,AAATPGLPK,9,569-577,13.2,
HLA-A*1101,GRA10,GVPAVPGLLK,10,507-516,17,
HLA-A*1101,GRA10,SVVEENTMAK,10,865-874,25.1,
HLA-A*1101,SAG2C,STFWPCLLR,9,13-21,9.3,P2
HLA-A*1101,SAG2C,ALLDHVFIEK,10,231-240,11.9,
HLA-A*1101,SAG2C,SSPQNIFYK,9,290-298,12.9,
HLA-A*1101,SAG2C,STTGVGETGK,10,163-172,28.4,
HLA-A*1101,SAG2C,GTEYSLALK,9,136-144,35.4,
HLA-A*1101,SAG2D,SSPQNIFYK,9,122-130,12.9,
HLA-A*1101,SAG2D,ALLEHVFIEK,10,63-72,20.2,P3
HLA-A*1101,SAG2D,SSAQTFFYK,9,290-298,1.8,
HLA-A*1101,SAG2D,TVYFSCDPK,9,154-162,5.3,
HLA-A*1101,SAG2D,PSSAQTFFYK,10,289-298,17.9,
HLA-A*1101,SAG3,VVGHVTLNK,9,80-88,15.4,
HLA-A*1101,SAG3,KQYWYKIEK,9,145-153,19.3,
HLA-A*1101,SRS9,TTCSVLVTVK,10,357-366,20.6,P4
HLA-A*1101,SRS9,AAASVQVPLK,10,140-149,29.9,
HLA-A*1101,SRS9,AIQSQKWTLK,10,169-178,35,
HLA-A*1101,BSR4,TTRFVEIFPK,10,284-293,10.3,
HLA-A*1101,BSR4,VSGSLTLSK,9,83-91,21.1,
HLA-A*1101,SPA,SSAYVFSVK,9,250-258,9.3,P5
HLA-A*1101,SPA,TSSAYVFSVK,10,249-258,12.2,
HLA-A*1101,SPA,YVFSVKELPK,10,253-262,18,
HLA-A*1101,SPA,KTEATYCYK,9,262-270,18.4,
HLA-A*1101,SPA,MTLMITRDSK,10,195-204,25.5,
HLA-A*1101,SPA,AVVSLLRLLK,10,89-98,6.5,
HLA-A*1101,SPA,VVSLLRLLK,9,90-98,7.2,
HLA-A*1101,MIC1,LTLTFISTK,9,338-346,13.8,P6
HLA-A*1101,MIC3,SVQLGSFDK,9,32-40,12.9,
HLA-A*1101,MIC4,SAVWFGVAK,9,16-24,17.2,
HLA-A*1101,MICA2P,GVMTPNQMVK,10,63-72,14.3,
,"1 Peptides derived from GRA10, GRA15, SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, MIC1, MICA2P were screened for potential supertype epitopes using the",,,,,
